BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment

15 Mar 2024
www.pharmaceutical-technology.com
Drug ApprovalClinical Study
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment
Preview
Source: Pharmaceutical Technology
The company says the tech leads to a speedier and cheaper drug development process. Image credit: Shutterstock/3rdtimeluckystudio.
Pi Health has launched on the clinical trial software-as-a-service (SaaS) market after completing a $30m Series A funding.
The US company, created as a subsidiary of BeiGene three years ago, has developed a platform to help increase patient enrolment in cancer trials.
Led by US venture capital firms AlleyCorp and Obvious Venture, the funding will now enable Pi Health to operate as an independent company.
Pi Health points to low participation rates of cancer patients in clinical trials and inefficient clinical trial infrastructures.
Pi Health offers what it terms Front-End Interoperable Capture Software (FOCS). The software, designed to connect sponsors and trial sites, automates manual processes for quicker data collection and a reduced administrative burden. The company says the tech leads to speedier and cheaper drug development cycles.
See Also:
FDA approves BeiGene’s TEVIMBRA for oesophageal cancer
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment
Preview
Source: Pharmaceutical Technology
Pi Health has also added one of the key buzzwords in the pharma industry, generative AI, to its platform. The algorithms can automate clinical documentation, patient matches to trials, and adverse event monitoring.
Pi Health CEO Geoffrey Kim said: “We’ve created an entirely new infrastructure for the clinical trial process, which has become mired in inefficiencies that impede progress.”
According to Kim, who was also deputy director of the Oncology Centre of Excellence at the US Food and Drug Administration (FDA), the company is well placed with its tech to help patients with cancer and other rare diseases.
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment
Preview
Source: Pharmaceutical Technology
Pi Health co-founders Bobby Reddy and Geoff Kim. Image credit: Keri Tan.
The plethora of SaaS options available for automating aspects of clinical trial workflows has recently undergone even further growth with the emergence of AI. One of the biggest issues in clinical trials, for example, is patient recruitment – AI platforms can help connect those living with cancer to clinical sites trialling experimental drugs.
Recent recipients of funding in the space also include Unlearn, an AI company creating digital twins of participants in clinical trials to allow smaller and faster studies. The US company raised $50m in Series C financing in February this year.
Israel-based QuantHealth has developed a platform, Katina, which simulates trial protocol combinations using AI. The company has raised $17m through Series A financing.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.